KSQ Therapeutics closes $80M Series C for cell therapy developed with CRISPR-based platform
The company aims to get its lead program, developed using its in-house "CRISPRnomics" platform, into the clinic in the next 18 months.
The company aims to get its lead program, developed using its in-house "CRISPRnomics" platform, into the clinic in the next 18 months.